Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16- substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion, and particularly, alkyl esters, such as the methyl ester, of such acids.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: Vinylstannyl derivatives and the processes for their conversion to vinyliodides, vinylbromides and vinyllithium reagents. The vinylstannyl, vinyliodides, vinylbromide derivatives and vinyllithiums are useful as intermediates for the preparation of prostaglandin analogs.

Abstract: This disclosure describes certain 6,9.alpha.-epoxy prostacyclines and their intermediates. These compounds are useful as bronchodilators and inflammatory mediator release inhibitors.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16- substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion, and particularly, alkyl esters, such as the methyl ester, of such acids.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: This disclosure describes certain 6,9.alpha.-epoxy prostacyclines and their intermediates. These compounds are useful as bronchodilators.

Abstract: The invention described herein relates to novel 15-deoxy-16-hydroxy-16-ethynyl or 16-(1-propynyl) prostaglandins of E, F, D and A series having on the terminal methylene carbon of the alpha chain a substituent selected from the group consisting of: ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl; R.sub.15 is selected from the group consisting of C.sub.1 -C.sub.4 alkyl, di-C.sub.1 -C.sub.4 -alkylamino, phenyl and phenyl substituted with one or more substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl, OR, SR, F or Cl, wherein R is an alkyl group.

Abstract: 15-Deoxy-16-hydroxy-16-ethynyl and 16-ethynylsubstituted prostanoic acids and congeners thereof, useful as bronchodilators, hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: 15-Deoxy-16-hydroxy-16-ethynyl and 16-ethynylsubstituted prostanoic acids and congeners thereof, useful as bronchodilators, hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: This disclosure describes certain 6,9.alpha.-epoxy prostacyclines and their intermediates. These compounds are useful as bronchodilators and inflammatory mediator release inhibitors.

Abstract: Vinylstannyl derivatives and the processes for their conversion to vinyliodides, vinylbromides and vinyllithium reagents. The vinylstannyl, vinyliodides, vinylbromide derivatives and vinyllithiums are useful as intermediates for the preparation of prostaglandin analogs.

Abstract: The invention disclosed herein relates to pharmacologically active prostaglandins of the E and F series in which C-16 is substituted with hydroxyl and fluoromethyl, difluoromethyl or trifluoromethyl as well as the pharmacologically acceptable, non-toxic lower alkyl esters and salts thereof, and to the intermediates and processes for producing such compounds.

Abstract: The invention disclosed herein relates to pharmacologically active prostaglandins of the E and F series in which C-16 is substituted with hydroxyl and chloromethyl or bromomethyl as well as the pharmacologically acceptable, nontoxic lower alkyl esters and salts thereof, and to the intermediates and processes for producing such compounds.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators, as hypotensive agents and as agents for the control of excessive gastric secretion.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: 15-Deoxy-16-hydroxy-16-ethynyl and 16-ethynylsubstituted prostanoic acids and congeners thereof, useful as bronchodilators, hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: This disclosure describes esters having prostaglandin-like activity of 15-deoxy-16-hydroxy-16-substituted-prostanoic acids formed by replacing the hydroxy group of the C.sub.1 -carboxylic acid substituent with para-acetamidophenoxy, methylsulfonylamido, para-acetylphenoxy, para-phenylphenoxy, C.sub.3 -C.sub.10 cycloalkoxy, arylalkoxy wherein the alkoxy group has from 7-12 carbon atoms, phenoxy or phenoxy substituted with 1-3 chlorine atoms or C.sub.1 -C.sub.3 alkyl, phenacyloxy or phenacyloxy ring-substituted with from 1-3 bromine atoms, a nitro moiety, C.sub.1-C.sub.8 arylalkyl, or arylalkoxy wherein the alkoxy group has from 7-12 carbon atoms; substituted arylamino (C.sub.1 -C.sub.12), substituted-naphthoxy, fluorenoxy, carboxyalkoxy (C.sub.5 -C.sub.